Ruby Lu

Ruby Lu is a reputable Venture Capitalist with a keen focus on supporting ambitious entrepreneurs dedicated to establishing enduring companies that make a positive impact on society.

With an impressive track record, Ruby has overseen 9 IPOs, including 5 on NYSE, 1 on Nasdaq, 1 on HKSE, and 2 on the Shanghai Stock Exchange. Additionally, she has 4 unicorns in the pipeline to go public in the next 2-3 years, with Kuaishou being one of her standout successes, generating billions in profit and over 1000x ROI from the initial investment valuation.

Beyond IPOs, Ruby has facilitated 5 successful M&As, with notable deals such as Pactera to BlackStone, Tapulous to Disney, RavenTech to Baidu, LeDon to Alibaba, and 99bill to Wanda.

Ruby is deeply passionate about leveraging technology to address societal issues. Her investments in prominent healthcare startups like DXY, HaoDF, and SightAI aim to tackle the critical shortage of medical resources in our communities.

Drawing from nearly 20 years of experience, Ruby has served on the board of various companies, including 5 on NYSE, 2 on Nasdaq, 1 on HKSE, and 1 on the London Stock Exchange. She has held key positions such as Chair of special committees 4 times, Chair of compensation committees 5 times, and Chair of audit committees 2 times.

Ruby's educational background includes a Master's degree in Economics with a focus on Energy, Environment, Science, and Technology Policies from The Johns Hopkins University, as well as a Bachelor's degree in Economics from the University of Maryland Baltimore County.

Prior to her current role, Ruby was the Founder of Atypical Ventures, a Founding Member at ECARX, and the General Partner & Co-founder of DCM China at DCM Ventures. She also gained valuable experience as a VP at Goldman Sachs.